Broad immune cell populations

Broad immune cell populations refers to the diverse assembly of leukocytes that constitute the human immune system, including lymphocytes (T, B, and NK cells), myeloid cells (monocytes, macrophages, granulocytes), and dendritic cells [1]. These populations work in concert to provide innate and adaptive immunity, maintaining homeostasis by identifying and neutralizing foreign pathogens and abnormal host cells [2]. In a therapeutic context, this term is typically used to describe the collective target of agents that do not act on a single receptor but instead exert broad effects across multiple immune lineages [3]. Such therapies are frequently employed in the management of systemic autoimmune disorders, the prevention of organ transplant rejection, and the treatment of certain cancers [4]. However, because these treatments lack specificity, they often result in global immunosuppression, increasing the patient's vulnerability to opportunistic infections and other systemic toxicities [5]. Monitoring these populations via flow cytometry or complete blood counts is essential for assessing treatment efficacy and safety [6]. Modern drug development often seeks to move away from targeting broad populations toward more specific molecular targets to minimize off-target effects [7].

Other names

LeukocytesWhite blood cellsImmune system cellsPeripheral blood mononuclear cells (PBMCs)

Broad-spectrum immunosuppression, lymphocyte depletion, and inhibition of inflammatory cytokine production across multiple cell lineages.